European Society of Cardiology: 29 August-2 September 2009, Barcelona, Spain
|
From ACC ’09: Dr. Bhatt’s thoughts on the evolution of the Reach Registry and long term expectations
- Deepak Bhatt, MD
Chief of Cardiology
VA Boston Healthcare System Director
Integrated Interventional Cardiovascular Program
Brigham and Women's Hospital and the VA Boston Healthcare System Senior Investigator
TIMI Study Group Harvard Medical School
Boston, Massachusetts
Tune into Dr Hirsch as he discusses PAD and polyvascular disease
- Alan T. Hirsch, MD
Director, Vascular Medicine Program
Minneapolis Heart Institute
Abbott Northwestern's Vascular Center
Minneapolis, MN
Access interviews from Drs Goto and Mahoney to get their perspectives on the registry.
 Elizabeth M. Mahoney, Sc.D.
Associate Professor, University of Missouri – Kansas City School of Medicine.
Director, Health Economics and Technology Assessment
Mid America Heart Institute, Saint Luke's Hospital
Kansas City, MO
 Shinya Goto, M.D., F.A.C.C, F.A.H.A
Professor of Medicine (Cardiology)
Department of Medicine
Director and Chairman, Research Center of Metabolic Disease
Tokai University School of Medicine
Director, Department of Metabolic System Medicine
The Institute of Medical Science
 |
Goto S, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156:855-863.
|
Dr Joachim Röther discusses the the two-year analysis
Explore the intriguing recent data with Dr Röther, on the management and outcomes of patients with, or at high risk of, atherothrombosis.
Access interviews from Drs Bhatt, Steg, Ohman and Alberts to get their perspectives on the registry.
The importance of the REACH registry
Dr Gabriel Steg, Co-chair with Dr Deepak Bhatt of the REACH registry, outlines the essential information you need to know about this landmark registry of over 68 000 patients with atherothrombosis.
The REACH Registry: Results and implications
Dr Deepak Bhatt brings you up to date on the published and upcoming research from the Registry that will affect your practice.
One-year data results
High rates of MI or stroke were found in REACH Registry patients, especially in those with atherothrombosis in multiple beds, whether or not they were symptomatic. This suggests that "atherothrombosis should be addressed as a global arterial disease," note Dr Ph Gabriel Steg and colleagues.
 View the abstract to the paper, published in JAMA, and download the comprehensive slide kit (members only).
The REACH registry is a worldwide health survey and one of the biggest international epidemiological registries to date. Over 68 000 people worldwide are now participating, representing the entire spectrum of those at risk.
One-year follow-up data results have been published, and the overall retention rate after two years of follow-up has been very successful.
|
|
Interested in results from REACH Registry studies? Visit the Publications section for a complete listing of global and local articles.
Don't miss the latest issue of the REACH registry bulletin Investigators Update, formerly known as The Observer.
View the video proceedings of the Regional Investigator Meeting, held on 15 March in Chicago, IL, with special guest Dr Mark Alberts.
|
Dr Bhatt shares his vision for the Reach registry and how it can complement randomized clinical trial data.
Dr Steg previews some of the upcoming research that will come out of the Reach registry.
Dr Ohman describes how the Reach registry will shed more light on polyvascular disease.
Dr Alberts addresses the systemic nature of atherothrombosis.
